Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Binimetinib + Encorafenib in Adolescent BRAF+ Melanoma
NCT03878719Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of binimetinib and encorafenib in cutaneous melanoma (CM) (2 arms), sponsored by Pfizer. Primary endpoints: Time to Maximum Plasma Concentration, Maximum Observed Plasma Concentration and 3 more. Started Aug 2020; status: terminated.
02
Drugs
binimetinibencorafenib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT03878719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878719.